TRAVERE THERAPEUTICS, INC.
StreetZero Signal 68
About TRAVERE THERAPEUTICS, INC.
Travere Therapeutics, Inc. is a biopharmaceutical company focused on rare diseases, operating under the tagline 'in rare for life.' It was incorporated on March 10, 2011 in the United States and is publicly traded on NASDAQ under ticker TVTX. As of December 31, 2025, the company reported revenue of $100M-$500M, and as of January 31, 2024, it had 380 employees.
LATEST FUNDINGRule 144
$13.0M
Announced 2026-10-15
IN THE NEWS
- 🔗 Travere Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares | Travere
- 🔗 Travere Therapeutics grants awards covering 178,580 shares | TVTX Stock News
- 🔗 Travere Therapeutics - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 🔗 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMPLOYEES380
FOUNDED2011
HQSan Diego, CA, United States
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalRare DiseasesPublicNASDAQ
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Completed public offering of 9,703,750 shares of common stock at $21.00 per share plus pre-funded warrants in March 2023.
- Reports revenue of $100M-$500M as of December 31, 2025.
- Employs 380 people as of January 31, 2024.
- Regularly issues inducement equity grants covering tens of thousands of shares to new employees.
Ask StreetZero about TRAVERE THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account